Clinical Trial Update: A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema [Phase 3]

View source ↗

Summary

A Phase 3 study comparing 0.3 mg pegaptanib sodium to sham injections in diabetic macular edema completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Macular Edema
• Macular Edema
• Retinal Disease

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Macular Edema, Diabetic Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2013-07-15